SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
CTSO reported Q3 2026 results. The price and volatility reaction is pending.
CTSOearnings

Earnings reactions, page 3

CytoSorbents Corporation (CTSO) Q3 FY2026 earnings

November 13, 2026 · SharpeIQ Research Desk

Reported results

  • GAAP revenue was $9.7 million, an increase of 3% compared to $9.5 million in Q3 2025.
  • GAAP gross margin was 75% in Q3 2026, up from 70% in Q3 2025.
  • GAAP operating loss was $1.2 million, an improvement of 59% compared to an operating loss of $2.9 million in Q3 2025.
  • GAAP net loss was $1.8 million, or $0.58 per share, compared to $3.2 million, or $1.01 per share in Q3 2025.
  • Non-GAAP adjusted net loss was $1.5 million, or $0.48 per share, compared to a non-GAAP adjusted net loss of $2.6 million, or $0.83 per share in Q3 2025.
  • Non-GAAP adjusted EBITDA loss was $0.3 million, an improvement of 86% compared to a loss of $2.0 million in Q3 2025.

Notes

Share and per-share amounts for all periods presented reflect a 1-for-20 reverse stock split effected on September 8, 2026.

Price and volatility reaction

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-12 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →